South Wales, May 22 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "INNAGEN" on April 1. The details about the trademark application no. UK00004367652 published in the journal no. 2026/021 (May 22).
With HGF Limited as representative, Cellular Agriculture Ltd filed the trademark application for the below mentioned good(s)/service(s).
Class 5 : Pharmaceutical preparations; pharmaceutical preparations containing viral vectors for the delivery of gene therapies and vaccines; antibiotics; pharmaceutical and biological preparations for immunotherapy treatment; biopharmaceutical preparations; genetically engineered cells for medical use for production and supply of therapeutic proteins; biopharmaceuticals produced from microbial fermentation; pharmaceutical preparations, namely, antibacterial preparations, antifungal preparations, antiviral preparations, dermatological preparations, immunosuppressants, and tissue repair preparations; biopharmaceutical preparations in the field of biological tissue and organoid, namely, miniature or simplified biological organs; biological preparations for medical purposes; biological preparations for veterinary purposes; pharmaceutical and biological preparations, namely, immunoregulatory proteins for medical purposes; biological tissue cultures and organoid for medical and clinical use; biotechnological products, namely blood and blood-derived biologics and plasma proteins; biological tissue cultures for medical purposes; stem cells for medical purposes; regenerative medical products of stem cells; biologics in the nature of cells for medical use; biological preparations for use in cell cultures for medical purposes; biological tissue cultures for medical purposes; biological tissue cultures for veterinary purposes; engineered mammalian cells for medical or clinical use; insulin; products derived from recombinant DNA technology, namely, human recombinant insulin, proteins, and hormones; biopharmaceuticals for the treatment of immune system related and oncological diseases and disorders; antibodies; anti-CD20 recombinant monoclonal antibody for medical use; products derived from blood and products derived from recombinant DNA technology, namely, colostral antibodies being immunoglobulins, human albumin, blood clotting factor preparations, plasma volume expanders, blood proteins for therapeutic medical use; monoclonal antibodies for therapeutic use, namely, the treatment of medical conditions; vaccines; vaccine preparations; medical preparations; medical preparations, namely, cell based tissues and cell clusters for human and veterinary transplantation; cell culture media for medical or veterinary purposes; viral vector vaccines; pharmaceutical preparations containing viral vectors; biologic product preparations, namely, proteins, antitussives, interferons and interleukins; interferons and interleukins for use in treating viral and autoimmune diseases; Gene therapy components, namely, viral and non-viral vectors, transgenes, promoters, regulatory sequences, gene editing tools, and RNA therapeutics; biological preparations for use in medical and clinical gene therapy and cell therapy; pharmaceutical preparations for gene therapy and gene editing; synthetic peptides for pharmaceutical purposes; dietary supplements; nutritional supplements; media for maintaining mammalian cells and tissue, namely a medium for maintaining neuronal cell or tissue viability; solutions for perfusing, preserving, storing, and transfusing mammalian organs for medical purposes; chemically defined media and media supplements for the growth of mammalian cells in culture; microbiological culture media, animal blood sera, mammalian and insect cells, mammalian and insect cell culture media and cell culture reagents, all for medical or veterinary purposes, in particular, for biopreservation, cryostorage for cells and tissues, for use as components of biopharmaceuticals, and for general medical diagnostic use; medical diagnostic biochemical and biological reagents for use in detection or treatment, or other medical purposes; nutraceuticals containing exosomes for use as an ingredient in the manufacture of dietary supplements, beverages, food products, and food supplements; drug delivery systems in the nature of exosomes; exosomes for medical purposes; exosomes for therapeutic purposes; tissue engineered products using physiologic tissue that serves to facilitate growth of new bone in an implantation site; dietary and nutritional supplements; food supplements; dietary and nutritional supplements comprised in whole or significant part of peptides; Connective Tissue Growth Factor (CTGF) and anti-connective tissue growth factor antibodies for clinical and pharmaceutical use; prolyl hydroxylase inhibitors for clinical or pharmaceutical use.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004367652
Disclaimer: Curated by HT Syndication.
